What Happened?
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Medical Devices & Supplies - Specialty company Enovis (NYSE: ENOV) fell 10.2%. Is now the time to buy Enovis? Access our full analysis report here, it’s free.
- Surgical Equipment & Consumables - Diversified company CONMED (NYSE: CNMD) fell 3.1%. Is now the time to buy CONMED? Access our full analysis report here, it’s free.
- Healthcare Technology for Providers company Astrana Health (NASDAQ: ASTH) fell 5.7%. Is now the time to buy Astrana Health? Access our full analysis report here, it’s free.
- Healthcare Technology for Providers company Privia Health (NASDAQ: PRVA) fell 5.2%. Is now the time to buy Privia Health? Access our full analysis report here, it’s free.
- Research Tools & Consumables company Waters Corporation (NYSE: WAT) fell 4%. Is now the time to buy Waters Corporation? Access our full analysis report here, it’s free.
Zooming In On Enovis (ENOV)
Enovis’s shares are very volatile and have had 20 moves greater than 5% over the last year. But moves this big are rare even for Enovis and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 7 days ago when the stock dropped 4.9% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
Enovis is down 39.7% since the beginning of the year, and at $26.70 per share, it is trading 45.9% below its 52-week high of $49.33 from December 2024. Investors who bought $1,000 worth of Enovis’s shares 5 years ago would now be looking at an investment worth $286.82.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.
